Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP-376 Solution for Inhalation Given for 28 Days to Stable CF Patients

NCT00677365 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00677365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00677365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP-376 Solution for Inhalation Given for 28 Days to Stable CF Patients
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2008
Completion date
June 30, 2009
Enrollment
151 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis (cf)